Genetically Induced Obesity
InquiryThree Types of Genetic Obesity
Obesity is a disease that is closely related to genetic and environmental factors and is the main cause of multiple metabolic comorbidities such as insulin resistance, type 2 diabetes, and liver disease. Genetic obesity is divided into three types: monogenic obesity, syndromic obesity, and polygenic obesity. Monogenic obesity usually involves mutations in the leptin signaling pathway, resulting in appetite suppression pathways and activation of appetite pathways. Several genetic syndromes of syndromic obesity involve specific mutations that affect multiple systems and are characterized by obesity. Polygenic obesity is caused by the simultaneous presence of DNA variants in multiple genes. Analysis of genes involved in genetic obesity is essential to understand the mechanisms and pathways of obesity and develop future targeted and personalized treatments. Protheragen provides clients with unparalleled genetic obesity analysis services using advanced genomic and epigenomic technologies. We not only detect genetic changes in obesity model organisms but also provide actionable insights for the development of personalized treatment methods.
Fig.1 Genetic-based genetic obesity drugs. (Kalinderi, et al., 2024)
Unlock the Genetic Code of Obesity: Genetically Induced Obesity Analysis Service
At Protheragen, we have established a team of experts dedicated to obesity research, aiming to help clients address the multifaceted nature of this complex disease. We consider the Causes of Obesity, such as Genetic Obesity, Disease-induced Obesity, and Medication-induced obesity, in combination with environmental and lifestyle factors. We conduct in-depth metabolic and behavioral assessments to fully understand the condition of the model organism. Based on the results of the analysis, we develop new anti-obesity therapies for specific targets and conduct preclinical studies to test the safety and efficacy of the therapies.
Targets for Developing Anti-Obesity Therapeutics
Anti-Obesity Therapy Development
Preclinical Studies of Anti-Obesity Therapeutics
We provide clients with comprehensive preclinical studies of anti-obesity therapies using advanced Obesity Models. We provide detailed pharmacokinetic and pharmacodynamic as well as biological evaluations. Our expertise ensures accurate assessment of therapeutic efficacy while addressing potential safety issues through meticulous toxicity assessments.
To further study the genetic determinants of obesity, we use advanced technology to provide clients with professional obesity genetic testing services, including monogenic obesity gene test service and obesity gene panel test service.
Monogenic Obesity Gene Test Service
At Protheragen, our monogenic obesity gene test service is designed to identify specific gene mutations that contribute to obesity, especially in cases with family history and early onset. Through comprehensive genetic analysis, we pinpoint mutations in genes such as ADCY3, LEP, LEPR, POMC, MC4R, etc., which are critical for regulating body weight. Monogenic obesity gene test services provide reference information for the customized development of personalized therapies and preventive healthcare. We provide the following genetic testing services to our clients:
- ADCY3 Gene Test
- DYRK1B Gene Test
- LEP Gene Test
- NLGN2 Gene Test
- PCSK1 Gene Test
- PPARG Gene Test
- UCP3 Gene Test
- BDNF Gene Test
- KIDINS220 Gene Test
- LEPR Gene Test
- NR0B2 Gene Test
- PHIP Gene Test
- SH2B1 Gene Test
- CEP19 Gene Test
- KSR2 Gene Test
- MC4R Gene Test
- NTRK2 Gene Test
- POMC Gene Test
- SIM1 Gene Test
Obesity Gene Panel Test Service
The obesity gene panel test service is designed to provide a comprehensive overview of the genetic factors that may contribute to obesity. It involves the analysis of multiple genes simultaneously, providing a broad-spectrum genetic assessment. We use technologies such as next-generation sequencing (NGS) to detect various genetic variants that may affect genes such as appetite regulation, energy metabolism, and fat storage. This analysis is of great reference value for the early identification of high-risk patients and the development of targeted anti-obesity treatments. We provide the following obesity gene panel test services to our clients:
- Non-Syndromic Monogenic Obesity Panel Test Service
- Comprehensive Monogenic Obesity Panel Test Service
- Diabetes-Obesity NGS Panel Test Service
- Bardet-Biedl Syndrome Panel Test Service
Our genetically induced obesity analysis service process is as follows:
Sample Collection
Collect a biological sample (such as blood or saliva) for genetic testing. Blood samples are usually preferred for comprehensive genetic analysis, but saliva samples are also acceptable.
DNA Extraction and Preparation
The sample is stabilized using appropriate reagents to prevent degradation. The sample is then treated with a lysis buffer to break down the cell membrane and release the DNA. DNA is purified from the lysate using techniques such as column purification to ensure the removal of proteins and other contaminants. Finally, the quality and concentration of the extracted DNA are assessed for later genetic analysis.
Genetic Testing and Analysis
We use advanced technologies such as NGS to analyze the extracted DNA to identify genetic variants associated with obesity. The methods we use include but are not limited to:
NGS: Rapidly and accurately sequence entire genomes or specific gene groups to identify single nucleotide polymorphisms (SNPs), insertions, deletions, and other genetic variations.
Polymerase chain reaction (PCR): PCR is used to amplify small fragments of DNA to detect the presence of specific gene mutations associated with obesity.
Whole exome sequencing (WES): Sequencing of all protein-coding regions of genes in the genome is useful for identifying mutations associated with monogenic forms of obesity.
Genotyping arrays: Rapidly scan the genome for genetic variants known to be associated with obesity, making them useful for large-scale genetic studies.
Data Analysis
Our experts analyze genetic test data to link specific genetic variants to the obesity phenotype to provide a comprehensive overview of inherited obesity.
Project Report
We deliver all the test data, analysis results, and expert insights to you in a project report.
Workflow
Applications
- Study genetic mutations or variants associated with obesity to identify new therapeutic targets or biomarkers, thereby developing effective anti-obesity therapies.
- Study the distribution and determinants of obesity-related genetic variants in the population to obtain more information on the genetic epidemiology of obesity.
- Observe the genetic changes induced by new drugs or anti-obesity therapies in model organisms to help test the efficacy of anti-obesity therapies.
- Analyze metabolic changes caused by genetically induced obesity to gain a deeper understanding of obesity-related diseases such as diabetes and cardiovascular disease.
Advantages
- Sequencing technologies such as WES and NGS are combined to identify numerous genetic variants associated with obesity. These technologies provide high-resolution data to comprehensively evaluate individual genetic variants and their role in obesity.
- We integrate multi-omics approaches to provide a comprehensive picture of how genetic factors interact with metabolic processes. We use advanced bioinformatics to link genetic data with functional biomarkers to gain a deeper understanding of the mechanisms of obesity.
- We have a comprehensive genetic database that allows for extensive comparison and analysis of genetic variants associated with obesity. Our experts interpret genetic data and provide advice for the development of targeted therapies.
Publication Data
DOI: 10.3390/children11020153
Journal: Children
Published: 2024
IF: 2.0
Results: This is a narrative review article in which the authors analyze syndromic obesity such as Prader-Willi syndrome (PWS), Bardet-Biedl syndrome (BBS), and common monogenic obesity characterized by mutations in the leptin-melanocortin pathway. The article emphasizes that patients with genetic obesity should start food intake restriction, increase physical activity, and reduce carbohydrate intake from an early age. The authors discuss recent advances in drug treatment for genetic obesity, such as the MC4R agonist setmelanotide, and the glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and liraglutide. The authors also emphasize that specific drug treatments should be used based on the genetic background of genetic obesity.
Frequently Asked Questions
What is genetic-induced obesity analysis?
The genetic obesity analysis service is used to examine the genetic factors that cause obesity, which involves screening and identifying specific genes and mutations known to affect weight and metabolism. By analyzing sample DNA, scientists discover genetic tendencies for obesity, understand how these genes interact with environmental factors, and predict the likelihood of developing obesity-related diseases.
What information will I receive from the genetically induced obesity analysis service?
We use advanced genome sequencing and analysis to examine specific genetic markers associated with obesity, metabolic rate, fat storage, appetite regulation, and energy expenditure. The final report will provide information such as the gene sequencing method, sequencing data, analysis results, expert interpretation, etc. We will also provide targeted therapy development recommendations based on the sequencing results.
At Protheragen, our genetic obesity analysis services provide comprehensive solutions for understanding and managing genetic obesity. From advanced genetic technologies to actionable insights, our services accelerate our clients' genetic obesity research. If you have any ideas, please feel free to contact us to discuss project proposals.
Reference
- Kalinderi, K.; et al. Syndromic and monogenic obesity: new opportunities due to genetic-based pharmacological treatment. Children. 2024, 11(2): 153.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.